← Back to Analyst Consensus 
NBIX Buy
NEUROCRINE BIOSCIENCES INC
Current Price —
Implied Upside —
Analysts 37
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 3 reiterations from 3 firms
Next Earnings
Nov 2, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Oct 12, 2026 | BMO Capital | maintain | Market Perform → Market Perform | — | 53% |
| Sep 29, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Sep 11, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Sep 8, 2026 | RBC Capital | reiterate | Outperform → Outperform | — | 55% |
| Sep 3, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 13, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Aug 3, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 3, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Aug 3, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 31, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jul 31, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jul 31, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Jul 31, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Jul 31, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Jul 31, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Jul 31, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 31, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| Jul 31, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jul 21, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 17, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 13, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jul 13, 2026 | BMO Capital | maintain | Market Perform → Market Perform | — | 53% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jun 30, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| May 29, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 22, 2026 | Bernstein | initiate | — → Outperform | — | 52% |
| May 8, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| May 7, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| May 6, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| May 6, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| May 6, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| May 6, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| May 6, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| May 6, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 22, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 50% |
| Apr 10, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Apr 7, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Apr 7, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 7, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 7, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 6, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Mar 12, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 55% |
| Feb 24, 2026 | Wolfe Research | initiate | — → Outperform | $160 | 54% |
| Feb 17, 2026 | JP Morgan | maintain | Overweight → Overweight | $176 | 55% |
| Feb 17, 2026 | Truist Securities | maintain | Buy → Buy | $140 | 54% |
| Feb 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | $175 | 54% |
| Feb 12, 2026 | Citigroup | maintain | Buy → Buy | $204 | 54% |
| Feb 12, 2026 | RBC Capital | maintain | Outperform → Outperform | $177 | 55% |
| Feb 12, 2026 | BMO Capital | maintain | Market Perform → Market Perform | $140 | 53% |
Price Target Trend
May 18, 2026 Latest: $206.22 Oct 24, 2026
EPS Estimates
+1q $2.84
Lo: $2.13 Hi: $3.65
14 analysts 0y $10.27
Lo: $8.98 Hi: $11.40
17 analysts +1y $11.97
Lo: $8.37 Hi: $16.06
15 analysts 0q $2.76
Lo: $2.07 Hi: $3.39
17 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days